Companies: 10,795·Total market cap: $144.5T
Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

FATENASDAQHealthcare● Active
$1.91
$-0.07(-3.54%)
Market Cap$222627690
P/E Ratio—
52W High$2.88
52W Low$0.91
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Fate Therapeutics, Inc. (FATE) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · FATE · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-1.09fate eps ttm · fate earnings per shareEarnings history
PE Ratio (TTM)—fate pe ratio ttm · fate price to earningsPE Ratio deep dive
Revenue (TTM)$6.3Mfate revenue ttm · fate annual revenueFull revenue history
Dividend YieldNo Dividenddoes fate pay dividends · fate dividend yieldDividend history
Shares Outstanding118.8Mfate shares outstanding · fate floatShares outstanding history
Next EarningsAug 11, 2026Est.fate earnings date · fate next earningsEarnings history

Explore Fate Therapeutics, Inc. Data

fate stock data · financials
Market Cap$222.6Mfate market cap · fate valuation
Analyst Forecast$6 · Buy
DividendsNo Dividenddoes fate therapeutics, inc. pay dividends · fate dividend yield
Revenue$6.6M-51.24%fate therapeutics, inc. annual revenue · fate revenue
EarningsEPS $-1.15+29.88%fate earnings · fate eps
PE Ratio—fate pe ratio · fate price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$6.6M▼ 51.24% YoY
202320242025
fate therapeutics, inc. revenue · fate revenue 2025
FY 2025Net Income-$136.3M▲ +26.82% YoY
202320242025
fate therapeutics, inc. net income · fate profit 2025
FY 2025EPS$-1.15▲ +29.88% YoY
202320242025
fate eps · fate therapeutics, inc. earnings per share 2025
TTM:Revenue: $6.3MNet Income: -$129.9MEPS: $-1.09View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy31 analystsis fate a buy · fate analyst rating
Strong Buy
0
Buy
16
Hold
13
Sell
2
Strong Sell
0
12-Month Price Target
$4.00Low
$1.91Current
$5.50Avg Target187.96% upside
$7.00High
fate price target · fate 12 month forecast

Total: 31 · Buy rate: 51.6%

The FATE analyst consensus is Buy, based on ratings from 31 Wall Street analysts over the past 3 months. The average 12-month price target is $5.50, representing +187.96% upside from the current price of $1.91.

Stock Performance

Full History
1D-3.54%
1W-23.90%
1M-20.08%
3M+43.61%
YTD+94.38%
1Y+25.66%
5Y-97.59%

About Fate Therapeutics, Inc.

CEOBahram Valamehr
IPO DateOct 1, 2013
Employees181
CountryUS
Websitefatetherapeutics.com

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and va…

BiotechnologyHealthcareNASDAQUS

what is fate therapeutics, inc. · fate stock overview · fate therapeutics, inc. company profile · who is fate therapeutics, inc. ceo · fate NASDAQ · fate therapeutics, inc. headquarters · fate therapeutics, inc. business segments

About Stock Overview & Key Data

Fate Therapeutics, Inc. (FATE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 1, 2013. As of the latest trading session, FATE stock price is $1.91, with a market capitalization of $222.6M. The stock has returned +25.66% over the past 12 months and +94.38% year-to-date.

According to 31 Wall Street analysts, the consensus rating for Fate Therapeutics, Inc. stock is Buy, with an average 12-month price target of $5.50. In fiscal year 2025, Fate Therapeutics, Inc. reported revenue of $6.6M and net income of -$136.3M. For detailed data — including Fate Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Fate Therapeutics, Inc. (FATE) stock price is $1.91. The stock is traded on NASDAQ under the ticker symbol FATE. The 52-week range is $0.91 – $2.88.

FATE stock priceFATE quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice